Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 31, 2022
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
[ Thu, Mar 31st 2022
] - WOPRAI
Marc Goodman Maintained (AMLX) at Buy with Decreased Target to $31 on, Mar 31st, 2022
Marc Goodman of SVB Leerink, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Buy with Decreased Target from $50 to $31 on, Mar 31st, 2022.
Marc has made no other calls on AMLX in the last 4 months.
There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 0 agree with Marc's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Marc
- Umer Raffat of "Evercore ISI Group" Initiated at Buy on, Wednesday, February 2nd, 2022
- Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $35 on, Tuesday, February 1st, 2022
- Chris Shibutani of "Goldman Sachs" Initiated at Strong Buy and Held Target at $36 on, Tuesday, February 1st, 2022
